TX-1877, a bifunctional hypoxic cell radiosensitizer, enhances anticancer host response: Immune cell migration and nitric oxide production

International Journal of Cancer

Volumn 116, Issue 4, 2005, Pages 571-578

  Oshikawa, Tetsuya ^a   Okamoto, Masato ^a   Ahmed, Sharif U ^a   Furuichi, Sachiko ^a   Tano, Tomoyuki ^a   Sasai, Akiko ^a   Kan, Shin ^a   Kasai, Soko ^a   Uto, Yoshihiro ^a   Nagasawa, Hideko ^a   Hori, Hitoshi ^a   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Anticancer immunity; Chemokine; Cytotoxic T lymphocyte; Nitric oxide; Radiosensitizer

Indexed keywords

2 NITROIMIDAZOLE ACETAMIDE; CD4 ANTIGEN; CD8 ANTIGEN; NITRIC OXIDE; RADIOSENSITIZING AGENT; TX 1877; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INFILTRATION; CELL MIGRATION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME INDUCTION; HYPOXIC CELL; IMMUNE RESPONSE; IMMUNOPOTENTIATION; IN VITRO STUDY; INHIBITION KINETICS; LUNG METASTASIS; LYMPHOCYTE COUNT; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; TH1 CELL; TUMOR GROWTH;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL HYPOXIA; CELL MOVEMENT; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; MICE; NITRIC OXIDE; NITROIMIDAZOLES; RADIATION TOLERANCE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 23244445969     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21101     Document Type: Article

References (32)

1. Hori H, Nagasawa H, Terada H. Oxidants in the environment. In: Nriagu JO, Simmons MS, eds. Advences in environmental science and technology. New York: John Wiley and Sons. 1994, 425-43.
2. Coleman CN, Bump EA, Kramer RA. Chemical modifiers of cancer treatment. J Clin Oncol 1988;6:709-33.
3. Lee DJ, Pajak TF, Stetz J, Order SE, Weissberg JB, Fischer JJ. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjuvant to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study. Int J Radiat Oncol Biol Phys 1989;16:465-70.
4. Lee DJ, Cosmatos D, Marcial VA, Fu KK, Rotman M, Cooper JS, Ortiz HG, Beitler JJ, Abrams RA, Curran WJ, Coleman CN, Wasserman TH. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995;32:567-76.
5. Hori H, Murayama C, Mori T, Shibamoto Y, Abe M, Onoyama Y, Inayama S. KIH-802: 2-nitroimidazole-1-acetohydroxamate as a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 1989;16: 1029-32.
6. Nagasawa H, Bando M, Hori H, Satoh T, Tada T, Onoyama Y, Inayama Y. Radiosensitizing, toxicological, and pharmacokinetic properties of hydroxamate analogues of nitroimidazoles as bifunctional radiosentisizers/chemical modifiers. Int J Radiat Oncol Biol Phys 1992; 22:561-4.
7. Denny WA, Wilson WR, Hay MP. Recent developments in the design of bioreductive drugs. Br J Cancer 1996;27:S32-8.
8. Hori H, Jin CZ, Kiyono M, Kasai S, Shimamura M, Inayama D. Design, synthesis, and biological activity of anti-angiogenic hypoxic cell radiosensitizer haloacetylcarbamoyl-2-nitroimidazoles. Bioorg Med Chem 1997;5:591-9.
9. Inomata T, Ogawa Y, Nishioka A, Hamada N, Ito S, Kariya S, Yoshida S, Nagasawa H, Hori H, Inayama S. The immunopotentiation effects of the bifunctional radiosensitizer KIN-806 in comparison with its analogs KIN-804 and KIN-844. Oncol Rep 1999;6:1209-12.
10. Inomata T, Ogawa Y, Itoh S, Kariya S, Hamada N, Nishioka A, Yoshida S, Nagasawa H, Hori H, Inayama S. Lung metastasis suppression of the bifunctional new radiosensitizer KIN-806. Int J Mol Med 1999;4:257-60.
11. Kasai S, Nagasawa H, Yamashita M, Masui M, Kuwasaka H, Oshodani T, Uto Y, Inomata T, Oka S, Inayama S, Hori H. New anti-metastatic hypoxic cell radiosensitizers: design, synthesis, and biological activities of 2-nitroimidazole-acetamide, TX-1877, and its analogues. Bioorg Med Chem 2001;9:453-64.
12. Suit HD, Sedlacek RS, Zietman A. Quantitative transplantation assays of spontaneous tumors of the C3H mouse as allografts in athymic NCr/Sed-nu/nu nude mice and isografts in C3Hf/Sed mice. Cancer Res 1988;48:4525-8.
13. Lamon EW, Gatti RA, Kiessling R, Fenyo EM. Comparison of the allospecific and viral-specific immune responses to irradiated versus formaldehyde-fixed allogeneic Molony lymphoma cells in CBA mice. Cancer Res 1975;35:962-9.
14. Larrick JW, Fischer DG, Anderson SJ, Koren HS. Characterization of a human macrophage-like cell line stimulated in vitro: a model of macrophage functions. J Immunol 1980;125:6-12.
15. Kawamata H, Nakashiro K, Uchida D, Harada K, Yoshida H, Sato M. Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer 1997;70:120-7.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction. Anal Biochem 1987;162:156-9.
17. Timonen T, Saksela E. A simplified isotope release assay for cell-mediated cytotoxicity against anchorage-dependent target cells. J Immunol Meth 1977;18:123-32.
18. Ward SG, Bacon K, Westwick J. Chemokines and T lymphocytes: more than an attraction. Immunity 1998;9:1-11.
19. Bagaiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997;15:675-705.
20. Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 1991;51:3316-22.
21. Hockel M, Schlenger K, Knoop C, Vaupel P. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991;51:6098-102.
22. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;1:285-9.
23. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-7.
24. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
25. Xie K, Huang S, Dong Z, Juang SH, Wang Y, Fidler IJ. Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst 1997;89:421-7.
26. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, Fidler IJ. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995;181:1333-43.
27. Limin L, Kilbourn RG, Adams J, Fidler IJ. Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res 1991;51:2531-5.
28. Meßmer UK, Reed JC, Brune B. Bcl-2 protects macrophages from nitric oxide-induced apoptosis. J Biol Chem 1996;271:20192-7.
29. Schwarz MA, Lazo JS, Yalowich JC, Allen WP, Whitmore M, Bergonia HA, Tzeng E, Billiar TR, Robbins PD, Lancaster JR Jr, Pitt BR. Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide. Proc Natl Acad Sci USA 1995;92:4452-6.
30. Lotze MT. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg 1997; 226:1-5.
31. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001;91:2136-47.
32. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.